A daily low dose of aspirin, a common painkiller, has shown promising potential in reducing the risk of developing cancer, according to recent research. Previous studies have already highlighted aspirin's ability to lower the risk of colon cancer. A new Australian study, tracking nearly 10,000 adults aged 71 to 77 over five years, revealed that participants taking 100mg of aspirin daily experienced a 15 percent lower risk of developing cancer compared to those on a placebo.

The research indicated that aspirin was particularly effective in preventing cancer among older individuals, specifically those who did not smoke, had a lower Body Mass Index (BMI), and possessed a family history of cancer. A significant finding was the correlation with clonal haematopoiesis of indeterminate potential (CHIP), a condition characterized by age-related blood cell mutations that elevate cancer risk. The study determined that having CHIP in 10 percent of blood cells was the strongest predictor for aspirin's efficacy in lowering cancer risk.

Published in JAMA Oncology, the researchers suggested that CHIP might play a vital role in influencing aspirin's effectiveness, potentially by affecting the body's inflammatory pathways. Despite these promising results, the researchers acknowledged that further extensive research is crucial to conclusively prove aspirin's role in cancer prevention. They also noted the study's limitations, including its focus on "relatively healthy older white adults in Australia," suggesting that findings might differ with broader demographics or different ages of aspirin initiation. Previous studies have indicated that starting aspirin use at younger ages might yield different long-term cancer risk benefits compared to initiating it in older age.

While aspirin offers potential benefits, its long-term use is associated with risks such as stomach ulcers and bleeding. Scientists emphasize that if low-dose daily aspirin is considered for cancer prevention, these bleeding risks must be carefully weighed against the potential advantages.

Beyond cancer prevention, aspirin is widely recognized for its efficacy in reducing the risk of heart attacks and strokes. It is commonly prescribed to patients with coronary artery disease (CAD), also known as coronary heart disease, to thin their blood and mitigate the chances of a serious cardiac event. CAD, affecting 2.3 million people in the UK, occurs when heart arteries narrow due to fatty material (atheroma) buildup. Although patients with CAD have traditionally been advised to take aspirin lifelong, evidence supporting its long-term benefits and safety has been limited, warranting ongoing assessment.